MAPT and Alzheimer disease: The development of PET imaging biomarkers for tau and neurodegeneration offers an opportunity not only to visualize and quantify the pathophysiology in the living brains of AD, but also to investigate the interaction mechanisms of the tau spatial propagation and its cascading neurodegeneration (Lu et al., 2023; Schöll et al., 2016).